BioSpace News Archive

Job Trends

What You Need to Know to Become a Medical Science Liaison

BioSpace spoke with Dr. Samuel Dyer, CEO of The MSL Society, to find out everything you need to know to become a medical science liaison.

January 21, 2019
·
2 min read
·
Editorial Team
Business

GSK Chairman Sir Philip Hampton Steps Down Ahead of Company Split

Hampton has served as chairman of the board since 2015. He decided to part ways with the company as it plans to separate into two entities.

January 21, 2019
·
2 min read
·
Alex Keown
Deals

Amid Government Shutdown, Companies Try New Approaches to IPOs

Last year was a record year for biotech initial public offerings (IPOs), but 2019 is off to a slow and rocky start because of the government shutdown, which today is in its 31st day.

January 21, 2019
·
3 min read
·
Mark Terry
Policy

Chinese Government Takes Action Against CRISPR Researcher

China government officials told the Xinhua News Agency that the researcher who became world famous for using CRISPR on human embryos “will be transferred to public security authorities,” and the individuals involved in the research will be “severely dealt with according to the law.”

January 21, 2019
·
2 min read
·
Mark Terry
Deals

Kindred Biosciences Announces Pricing of Public Offering of 4,215,000 Shares of its Common Stock

Kindred Biosciences, Inc. today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share

January 21, 2019
·
5 min read
BioForest

Physician-Targeted Marketing Is Associated With Increase in Opioid Overdose Deaths

While lawsuits against opioid manufacturers wind their way through the courts, the new study shows a direct link to marketing efforts and overdoses.

January 21, 2019
·
3 min read
·
Alex Keown
FDA

FDA User Fees Will Run out by Feb. 8, Causing Delay in Drug Approvals Unless Shutdown Ends

The partial government shutdown is 31 days old, yet the U.S. Food and Drug Administration has maintained a steady list of drug approvals throughout that time. However, that approval rate could change next month.

January 21, 2019
·
2 min read
·
Alex Keown
Business

Interview: Opiant Focuses R&D Efforts on Battling Addiction and Overdoses

As Purdue Pharmaceutical’s OxyContin has become the poster child for opioid addiction, so too has another drug become synonymous with efforts to save people who have overdosed on those drugs – Narcan, developed by California-based Opiant Pharmaceuticals.

January 21, 2019
·
4 min read
·
Alex Keown
Drug Development

AbbVie’s ‘s Imbruvica Fails to Gain Traction in Pancreatic Cancer

The company provided an update on its Phase III trial of Imbruvica in combination with chemotherapy compared to placebo in metastatic pancreatic adenocarcinoma.

January 21, 2019
·
3 min read
·
Mark Terry
Business

OCR and ImaBiotech initiate a strategic partnership to provide in situ drug efficacy and target exposure services in Pets with naturally occurring tumors

OCR and ImaBiotech have announced the launch of a new preclinical service for Biotech-Pharma-MedTech companies that allows drug efficacy and target exposure services at cellular level using Pets with naturally occurring tumors.

January 21, 2019
·
4 min read